GlassScriptPhysician profile
Darwin R Boor
NPI 1730178419
$214.48
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2021: $21.61.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $46.46 | 2019 | |
| Alexion Pharmaceuticals, INC. | $25.89 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $21.61 | 2021 | |
| Mallinckrodt Enterprises LLC | $19.50 | 2019 | |
| Emd Serono, INC. | $16.81 | 2019 | |
| Bausch Health US, LLC | $15.35 | 2019 | |
| Acorda Therapeutics, INC | $15.24 | 2019 | |
| Biogen, INC. | $14.79 | 2019 | |
| Amgen INC. | $14.12 | 2019 | |
| Pfizer INC. | $12.38 | 2019 | |
| Mdd US Operations, LLC | $12.33 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darwin Boor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.